The pharmacological agent outperforms current drugs in most of cases, show multiple experiments
A new pharmacological agent demonstrates promising results for the prevention of a wide range of heart rhythm disorders, including both cardiac and brain injury-induced arrhythmias. Furthermore, the compound (SS-68) demonstrates significant activity in conditions of reduced blood flow to the heart caused by obstructed arteries.
Each year, more than 17 million people from around the globe (mostly Europe and the USA) die of cardiovascular diseases and related complications, according to the World Health Organization. In Russia, about 3 out of 1,000 people suffer from the most common and malignant heart rhythm disorder: atrial fibrillation (AF), where the count is expected to at least double in the next 30 years. While sometimes lacking symptoms, atrial fibrillation could generally be recognised by a racing, irregular heartbeat, dizziness, fatigue, shortness of breath and chest pain, thereby largely compromising the quality of one’s life. The disorder could also lead to various complications, including dementia, stroke and heart failure.
Currently, the drugs administered to AF patients have major deficiencies, including narrow therapeutic windows, which means that even minimal imprecision in the dosage could result in unacceptable toxicity. Hence, patients need to be closely monitored and have their doses adjusted on a regular basis.
In their study, the team turned to the aminoindole derivatives to look for an alternative compound. This chemical group has already shown a significant potential in terms of cardio-pharmacological activity.
Having tested the SS-68 compound on multiple occasions in different animals, the researchers report that it has a pronounced antiarrhythmic effect and is able to bring the electrical activity of the heart back to normal and, in most cases, outperforming the reference drugs used in clinical practice: amiodarone, lidocaine, aymaline, ethacizine, etmozine and quinidine anaprilin.
Further, in brain injury-induced arrhythmias, the compound was found to reduce the episodes of epilepsy. It was also observed to have a positive effect in clogged blood vessels where it is reported to have successfully increased the coronary blood flow. In addition, the compound managed to decrease the area of necrosis in the heart tissue caused by a heart attack.
“To date, there have been significant achievements of Russian and foreign pharmacologists, chemists and clinicians in creating and introducing into the practical medicine a number of antiarrhythmic drugs different by their chemical structure, nature, spectrum, activity and mechanism of action; nevertheless, one of the most important tasks of modern pharmacology is searching for and developing new highly active substances of the corresponding action,” explain the scientists.
“Special attention should be paid to an in-depth study of the molecular mechanisms of action of this compound,” they conclude.
A paper looking further into the molecular mechanisms of the antiarrhythmic action of SS-68 prepared by the same research team is currently in press with Research Results in Pharmacology.
The Latest on: Pharmacological agent
[google_news title=”” keyword=”pharmacological agent” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pharmacological agent
- The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headacheon February 27, 2024 at 4:00 pm
for acute severe migraine and pharmacological agents for prophylaxis of migraine. Sumatriptan, naratriptan and others, referred to as 'triptans', are the mainstay for acute treatment of migraine.
- A Stress Neurobiologist Reveals the Key Thing We Are All Missing For Good Mental Healthon February 26, 2024 at 7:45 am
Yet if you give them antidepressant drugs, they keep going. These types of paradigms have shown their validity in studies of pharmacological agents used in human psychiatry, and so they’re ideal for ...
- Heron Therapeutics (HRTX) Price Target Increased by 18.52% to 6.80on February 23, 2024 at 4:06 pm
The average one-year price target for Heron Therapeutics (NasdaqCM:HRTX) has been revised to 6.80 / share. This is an increase of 18.52% from the prior estimate of 5.74 dated January 16, 2024. The ...
- Could Niacin Actually Induce Heart Disease?on February 18, 2024 at 4:00 pm
such as when provided as an over-the-counter supplement or as a pharmacological agent for cholesterol lowering," Hazen's group noted. Ultimately, the findings "raise the question of whether a ...
- Why You Shouldn't Wrap Your Food In Aluminium Foil Before Cooking Iton February 17, 2024 at 7:32 pm
If you're baking fish, roasting vegetables or preparing a piece of meat for dinner tonight, chances are that you'll wrap your food in aluminium foil ...
- Pharmacological Options in the Management of Orthostatic Hypotension in Older Adultson February 14, 2024 at 4:00 pm
Bearing in mind the potential underlying pathophysiological processes contributing to OH, pharmacological agents can also be used to improve symptom control in affected patients, principally after ...
- Insomnia Disorderon January 31, 2024 at 4:00 pm
In such cases, Food and Drug Administration (FDA)–approved pharmacologic agents (discussed below) are recommended for short-term use. In patients with chronic insomnia, appropriate treatment of ...
- Gastroesophageal Variceal Hemorrhageon January 29, 2024 at 2:15 am
An important new approach to treatment has been the use of pharmacologic agents such as octreotide in combination with endoscopic therapy. The addition of octreotide (or vapreotide) to endoscopic ...
- Study shows that human beliefs about drugs could have dose-dependent effects on the brainon January 3, 2024 at 8:20 am
This effect was previously thought to apply only to pharmacologic agents. A similar dose-dependent effect of beliefs was also found in the functional connectivity between the thalamus and the ...
via Bing News